potassium voltage-gated channel subfamily A member 2Genealiases: DEE32 · EIEE32 · HBK5 · HK4 · HUKIV · KV1.2
Q-omics provides the consensus-scored KCNA2 profile across patient tissues and cancer cell-line models. KCNA2 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, KCNA2 is differentially expressed in 11, with the highest sampling consensus in BLCA. Additionally, KCNA2 RNA expression shows 17,853 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight HNSC, BLCA, and GBM as cancer lineages where KCNA2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KCNA2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KCNA2 survival associations across molecular data types. KCNA2 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (9) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KCNA2 RNA expression–survival associations across cancer types. High KCNA2 expression shows favorable associations in HNSC, LUAD, OV, SKCM, CHOL and CESC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for KCNA2 RNA expression.
This table summarizes KCNA2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in BLCA for RNA.
This table ranks reproducible tumor–normal expression differences for KCNA2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KCNA2 shows lower tumor expression in BLCA, THCA, STAD, BRCA, COAD and PAAD. The BLCA box plot shows higher KCNA2 RNA expression in normal versus tumor tissue (log2 FC = −0.515, t-test p < 0.001).
This table shows molecular features associated with KCNA2 in patient tissues and cancer cell lines. In patient samples, KCNA2 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, KCNA2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUSC and BONE.
